Total Voting Rights

RNS Number : 0952K

Oxford Biomedica PLC

03 May 2022

 

Oxford Biomedica

Total Voting Rights

Oxford, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 29 April 2022 consisted of 96,063,479 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

The Company's TVR issued on 01 April confirmed an issued share capital of 96,064,224 Ordinary Shares which included 745 Ordinary Shares issued and allotted in error.  This has now been reversed and accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 96,063,479.

The above figure (96,063,479) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector^® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.  

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .

 

END

 

 

TVREANSDEDDAEEA